We performed anthralin comparative study(0.01% vs 0.1%) to assess the effectiveness of low-strengh anthralin therapy in 34 psoriatic patients and the resu1ts can be summarized as follows. 1. In the case of 13 patients using Burdick UVB larnp, in 1 patient the effect of 0.1% anthralin was superior to that of 0.01% anthralin from the start to the end of treatment, in 5 patients(38.5%) initially the effect of 0.1% anthralin was superior but in time became equal to that of 0.01% anthralin, and in 7 patients (53.8%) the effect of either side was same throughout the courae of the treatment. In the case of 21 patients using Waldmann UVB cabinet, there were 2(9.5 %), 3(14.3%) and 16 patients(76.2%) in the order named above. 2. The side effect of 0.1% anthralin was more severe than or at least the same as that of 0.01% anthralin in every patient who complained about side effects. So low-strengh anthalin-UVB phototherapy was thought to be the effective and alternative method of treatment particularly for the purpose of lessening the side effects.
Anthralin* ; Humans ; Phototherapy ; Psoriasis*

Our Study was performed to evaluate the effect of anthralin for the treatment of psoriasis. Thirty seven patients with mild form of psoriasis were trested with topical anthralin ointment. 1. Twenty patients(54%) showed clearing of lesion within 8 weeks. 2. Treatment with anthalin was failed in 15 patients(40.5%). 3. Side reaction such as staining, pruritus and erythems was noted in 18 patients (48.6%), among them, 8 patients(21.6%) terminated the therapy with anthralin due to marked side reaction.
Anthralin* ; Humans ; Pruritus ; Psoriasis*

Our study was performed to evaluate the efficacy of anthralin-UVB therapy on patients with psoriasis. We studied twenty two patients suffering from plaque-type psoriasis of varying degrees of severity. The results can be summarized as follows. l. 2p patients(90.9%) out of the total 22 patients showed grade 4 improvement. The rernaining 2 patients failed to respond to treatment, 2. Arnong the improved 2Q patients, 2 patients who were treated more than 3p times for grade 4 improvement were excluded, so cleared patients were 18(81.8%). 3. Arnong the 18 cleared patients, the mean nurnber of therapy wasg. 6 for grade 3 and 12. 5 for grade 4 in the cases of trunk lesiona, and 13. 2 for grade 3 and 17. 8 for grade 4 in the cases of extrernities lesions. With above results, anth-ralin-UVB therapy was rnore effective in lesions of the trunk than in those of extremi.ties. 4. Notable side effects were pruritus in 6 patients(27.3pg), staining in 4 patients (18,2%), and 1ITltatioB in 2 patients(9.1%)
Anthralin* ; Humans ; Phototherapy* ; Pruritus ; Psoriasis*

Alopecia areata (AA) is a recurrent, nonscarring type of hair loss. Although it is a medically benign condition, AA can cause great emotional distress to affected patients and their family. At this time, there are many treatments that have varying efficacies but there is no reliable cure. Topical anthralin treatment of AA has been found to be effective by some researchers. We experienced two cases of AA improved by topical anthralin therapy without serious side effects. Anthralin is much less expensive than most other topical therapies for AA and relatively well tolerated. In our experience, it is more effective in eliciting a cosmetic response than other topical treatments. Anthralin appears to be a reasonable therapeutic option for AA.
Alopecia Areata* ; Alopecia* ; Anthralin* ; Hair ; Humans

Anthralin is highly efficacious in the treatment of psoriasia, but it has two major drawbacks: staining of the skin and clothing and irritation of the skin. There have been several studies that the effect of the anthralin with short contact therapy(SCT) is nearly the same as that with the simple application(SA). This study was planned to compare the effect and side effects of SCT with those of SA of anthralin in 27 psoriatic patients visited between November 1982 and June 1983 at the Department of Dermatology, Seoul National University Hospital. The results could be summerized as follows: 1. For 4 weeks of treatment, the longer the duration of treatment, the more similar the effect between the SCT and the SA. 2. After 2 weeks of treatment, the effect of the SA was better than that of the SCT in 5 cases, the same in 18 cases and worse in 1 case. 3. For 4 weeks of treatment, all side effects(irritation, ataining and pruritus) were more frequent in the SA than in the SCT. And irritation was observed earlier than staining. 4. After 2 weeks of treatment, the side effects of the SA were more than those of the SCT in 12 cases and the same in 12 cases. With all our results, we have concluded that the patients who cannot tolerate the SA could be tried with the SCT.
Anthralin* ; Clothing ; Dermatology ; Humans ; Psoriasis* ; Seoul ; Skin

Both irritation and staining reaction of anthralin on the skin are the two most important problem of therapy. Irritation, such as erythema, edema and staining by p. lg anthralin ointment were studied with the chamber-testing technique in 21 psoriatic patients. We campared the skin reaction of short exposure time, such as 1 hour, 2 hours, and 3 hours with those of exposure of 24 hours through 3 days after application. The results were as follows: l. Incidence of erytherna reaction was 81.9% in exposure of 1 hour, 85.7%, in 2 hours, 90.5%, in 3 hours and 100% in exposure of 24 hours. Degree of erythema reaction was increased according to duration of application. 2. There were no edematous reactions in exposure of 1 hour or 2 hours, 9,5% in 3 hours and 28,6% of grade 1 reaction in 24 hours. 3. There was no staining reaction in exposure of 1 hour, 48% in 2 hours, 9.5%, in 3 hours and 71.4% in 24 hours. Degree of staining reaction elicited by short exposure time were all weaker than reaction caused by 24 hours exposure.
Anthralin* ; Edema ; Erythema ; Humans ; Incidence ; Skin*

BACKGROUND: The Ingram regimen has been advocated for t.he treatment of psoriasis. It is an effective therapeutic moiality, but its complexity and frequent side reactions have restricted its use for therapy. There are several modified Ingrarn regimen, change of vehicle, shortening of application time, low-strerigth anthralin, combination with emollient. Previously, we have reportved the effectiveness of mocified Ingram regimen for psoriasis, however, the remission time and relapse rate of psoriasis has not been reported in Korea. OBJECTIVE: This study was performed to evaluate the efficacy of the modified Ingram region for the treatment of psoiasis and the remission time and relapse rate of psoriasis following moclified Ingram therapy. METHODS: Sixty patients with plaque-form psoriasis were treated with the modified Ingra,n therapeutic regimen. They were divided into two groups, a moderate group which included 39 patients, and 21 patients in a severe group. RESULTS: The follwing results were obtained from this study. 1. Among 60 patients, 52 patients(86.6%) were successfully healed and 8 patients(13.3%) showed failure in their t eatment. 2. In 52 patients, 44 patients(73.3%) showed a clearing of psoriasis, 8 patients(13.3%) showed some improvement. 3. In 44 cleared patients mean numbers and duration of therapy reaching grade 4 were 13.0 and 21.0 days for the trunk and 15.1 and 24.7 days for the extremities, the difference was not significant statistically(p>0.05). The difference between the total dose in trunk and extremitis was significant statistica,ly(p<0.05). 4. In 44 cleared patients mean numbers, duration and total dose of therapy reaching grade 4 in the severe group were significantly higher than those in the moderate group (p<0.05). 5. There were some rotable side effects such as staining(17.3%), erythema(15.4%) and pruitus(13.5%), but in no case therapy was terminated. 6. According to the everity in 33 of the cleared patients, we observed 10 patients(17.4%) with early relapse((6 months), 7(21.7%) with late relapse(>6 months) and 14(60.9%) with riorelapse(>12 months) in the moderate group and also observed 10 patients(70.0%) with early IP, lapse, 2(20.0%) with latrelapse and 1(10.0%) with no relapse in the severe group. 7. In 33 pat,ients who were followed up at least one year later, the mean time of remission was 31.4 months in the moderate group and 6.0 mont,hs in the severe group. There were signilicant differences in the two groups(p<0.05). CONCLUSION: The results of this study suggest that the modified Ingram regimen is one of the effective therapeutic mocialities for cases of moderate psoriasis.
Anthralin ; Extremities ; Humans ; Korea ; Psoriasis* ; Recurrence

OBJECTIVES: To assess the efficacy and safety of excimer laser in combination with topical standard therapies for treatment of plaque-type psoriasis in comparison to excimer laser alone, standard topical treatment alone, or placebo.

METHODS: A literature search using Medline, Cochrane and HERDIN was conducted. Data were analyzed using mean difference at 95% confidence interval, with heterogeneity determined by I2 test.

RESULTS: Three articles with total of 130 patients fulfilled the inclusion criteria. Topical treatments studied were vitamin analog (calcipotriol), anthralin (dithranol), and steroid (flumethasone pivalate). A subgroup analysis comparing combination therapy and excimer laser alone showed a greater reduction in pooled PASI score reduction (-2.52; 95% CI: -4.28, -0.77) in the combination group after five to six weeks. There was also a significantly greater reduction in cumulative UVB dose (-3.29; 95% CI: -4.29, -2.30) needed for clearing in the combination group. Pigmentation was the commonly observed adverse event in both groups.

CONCLUSIONS: Excimer laser, in combination with topical treatment, is more effective than excimer laser alone, with significantly lower cumulative UVB dose, but the quality of current evidence is low. Long-term controlled trials are warranted to increase our confidence in the estimates of these outcomes.

BACKGROUND: Extensive alopecia areata (EAA) is resistant to multiple individual treatment modalities and has poor prognosis for cosmetically adequate regrowth. Anthralin is a widely used topical anti-psoriatic drug that may have an immunomodulating effect on AA as is does in psoriasis. But, there has only been small number of clinical trials of anthralin in the treatment of AA. OBJECTIVE: The purposes of the study were to evaluate the efficacy, prognostic factor, side effects and recurrence rate of topical anthralin therapy in treatment-resistant EAA. METHODS: A total of 16 cases of EAA (>50% scalp hair loss) who had failed in previous treatments were subjected in this study. Anthralin in 0.5% concentrations was applied to alopectic lesions for 1 hour daily over 4 weeks, gradually increasing anthralin concentration until low-grade erythema and pruritus develops. Treatment was withdrawn after complete response or if there were no signs of improvement at 6 months. Responders were followed up for 6 months after discontinuation of therapy. RESULTS: The overall response rate was 62.5%, complete response (>90% regrowth or cosmetically acceptable appearance) was obtained in 25% of cases and, good response (50~99% regrowth) in 39.5% of cases. In this study, among the investigated prognostic factors, there were no statistically significant factors (p<0.05, Fisher exact test). The most frequent side effects were therapeutically induced mild pruritus (93.8%), erythema (93.8%) and scale (56.3%). Other side-effects were transient folliculitis (31.3%) and regional lymph adenopathy (12.5%). Relapse was observed in 60% of responders after 6 month of follow up. CONCLUSION: Topical anthralin for treatment-resistant EAA is an effective therapy with tolerable side effects. Therefore, we propose the topical anthralin as a reasonable therapeutic option for treatment-resistant EAA.
Alopecia ; Alopecia Areata ; Anthralin ; Erythema ; Folliculitis ; Hair ; Prognosis ; Pruritus ; Psoriasis ; Recurrence ; Scalp

Retinoid, Ro l0-9359 is an aromatic analog of vitamin A acid or retinoic acid. The orally administrable retinoid has a therapeutic effect on the treatment of psoriasis, ichthyosis, Darier's disease, pustulosis palmoplantaris and skin cancer. However, some results have been reported previously, indicating that oral retinoid alone does not clear psoriatic lesions although some improvement may he noted. Morcover, promising results of combination treatment of psoriasis with the retinoid and local dithranol or PUVA have been reported. In the present study we report the clinical results obtained in 16 psoriatics after oral retinoid treatment, with and without the addition of topical cotricosteroid. We employed a new retinoid regimen orally in 16 adults with widcspread psoriatic lesions, Most of them bad been treated earlier with topical corticosteroids without beneficial effect. Of 16 cases 8 were treated with retinoid alone and the other 8 patients with topical corticosteroids in addition to the oral regimen, The results are summarized as follows: 1. Complete to good clearing of the lesions was seen in 5 of 8 patient with retinoid alone and in 7 of 8 patients using the combination treatment. 2. Side-effects appeared in all patients, the most prominent being dryness of the mouth or cheilitis in cases and pruritus in 10 cases. However, there were no abnormalities shown in liver function tests during or after treatment. From the above results the combination treatment with topical corticosteroids seems to be more effective than retinoid alone in the treatment of psoriasis. It is considered that the oral retinoid could be an alternative on the treatment of psoriasis.
Adrenal Cortex Hormones ; Adult ; Anthralin ; Cheilitis ; Darier Disease ; Humans ; Ichthyosis ; Liver Function Tests ; Mouth ; Pruritus ; Psoriasis* ; Skin Neoplasms ; Tretinoin